Canaccord analyst John Newman raised the firm’s price target on Candel Therapeutics (CADL) to $25 from $20 and keeps a Buy rating on the shares. The firm said its CAN-2409 shows significant median Overall Survival improvement from the control arm.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Promising Potential of Candel Therapeutics’ CAN-2409: Analyst Recommends ‘Buy’ Based on Compelling Phase 2 Trial Results and Future Outlook
- Candel Therapeutics Reports Positive Phase 2 Trial Results
- Candel Therapeutics announces overall survival data from Phase 2 CAN-2409 trial
- Walmart reports Q4 beat, Salesforce in cloud talks with Microsoft: Morning Buzz
- Candel Therapeutics initiated with a Buy at Citi